The risk of AD in APOE4-ε4 carriers has been reported to be greater in females (Riedel et al., 2016) but recent evidence indicated that having 1 copy of APOE4-ε4 was associated with similar risk of AD in men and women between the ages of 55 and 85 years, whereas a greater risk was observed in women aged 65–75 years (Neu et al., 2017). Here, APOE is linked to Alzheimer disease.